SEATTLE, Nov. 4, 2020 /PRNewswire/ -- CTI BioPharma
Corp. (Nasdaq: CTIC) today announced an oral presentation
supporting the Company's pacritinib development program in graft
versus host disease (GVHD) at the 62nd American Society
of Hematology (ASH) Annual Meeting & Exposition, being held
virtually December 5- 8, 2020.
The details of the presentation are as follows:
Abstract Title: Biological and Clinical Impact of
JAK2/mTOR Blockade in GVHD Prevention: Preclinical and Phase I
Trial Results
Session Name: Clinical Allogeneic Transplantation;
Acute and Chronic GVHD, Immune Reconstitution Phase I and II
Trials
Session Number: 722
Session Date: Sunday, December 6, 2020
Session Time: 9:30 a.m. - 11:00
a.m. PT
Presentation Time: 10:00 a.m. PT
Presenter: Dr. Joseph
Pidala
A copy of the abstract is available here.
About CTI BioPharma Corp.
We are a biopharmaceutical company focused on the acquisition,
development and commercialization of novel targeted therapies for
blood-related cancers that offer a unique benefit to patients and
their healthcare providers. We concentrate our efforts on
treatments that target blood-related cancers where there is an
unmet medical need. In particular, we are focused on evaluating
pacritinib, our sole product candidate currently in active
development, for the treatment of adult patients with
myelofibrosis. In addition, we have recently started developing
pacritinib for use in hospitalized patients with severe COVID-19,
in response to the COVID-19 pandemic. We are headquartered in
Seattle, Washington.
CTI BioPharma Investor Contacts:
Maeve Conneighton/Maghan Meyers
+212-600-1902
cti@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-announces-oral-presentation-at-the-62nd-american-society-of-hematology-meeting-301166463.html
SOURCE CTI BioPharma Corp.